Dr. Amy Pomeroy

I've developed a model of combination chemotherapy and trained it on DLBCL trials. The ultimate test of my model is to predict new trial results, so I predicted the results of the POLARIX trial. Today I got to check the predictions, and they were right! bit.ly/3yuf0MC

'Less is more' maintenance therapy in #MultipleMyeloma! Triplets→ASCT→3yr Len → D/C if MRD-neg (NGF+PET/CT-neg) Results: 3yr PFS ~93%, TFS ~75% *Treatment initiated for MRD resurgence Based on @bdermanmd 's MRD2STOP + this data: I'm comfortable stopping Len in standard-risk MRD-neg patients at 3yrs! However, with quad induction + MRD-neg 10^-6 by NGS, do we even need 3yrs of Len? As @End_myeloma reminds us, Len maintenance was built on the backbone of doublets! tinyurl.com/8thww4sz

A very well-written and thoughtful piece from Itai Yanai and Martin Lercher, with a nice visual showing how we “trim the tree” of the process, for publication. On a related note, I’d like to see more Math Onco papers show the discovery process within papers — e.g. the process of model selection!

i'm just a senior postdoc, standing in front of a career that i have worked really hard for, asking higher education in the united states to not completely implode in front of my eyes before i even get a chance to say the words 'my lab studies'

@ac_palmer @AmyEPomeroy @BCD_AACR Congratulations @ac_palmer @AmyEPomeroy !!! Fantastic to see this work out!

New paper by @AmyEPomeroy! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma Out now in Blood Cancer Discovery @BCD_AACR doi.org/10.1158/2643-3… #mathonc #lymsm #BloodCancer 1/n

First author Amy Pomeroy presents her recently published work in Blood Cancer Discovery: A model of curative combination therapy for lymphoma by @amyEpomeroy and @ac_palmer. Read the article: brnw.ch/21wRb8A

Dr. Amy Pomeroy @AmyEPomeroy is up next in our postdoc spotlight session telling us about their work on mechanistic modeling of combination therapy

New de-novo TCR design preprint from @DhuviKarthikey1 just dropped: TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences biorxiv.org/content/10.110…

Kudos to @brian_rini for accurately describing the effects of combination therapies :)

@SC_Patterson has been studying choriocarcinoma (cancer of the placenta) and I was initially so surprised when her cells for a cancer exclusive to patients with XX chromosomes were XY. The placenta is such a fascinating organ.

📌 Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). Great talk by @LoiSher @OncoAlert #ASCO24 #BreastCancer ✔️the largest study ➡️8% positive for ctDNA at baseline ➡️ ctDNA detection was highly prognostic of worse outcomes, particularly for patients who were persistently positive

Common Sense Oncology chapter is now live in ASCO Ed Book. Check it out. ascopubs.org/doi/pdf/10.120… We also have a @csoncol session at #ASCO24 Monday morning 8AM!

To make sure that the university represents the entire state we need programs that represent other underrepresented populations. The UNC System has eliminated the current mechanism to support diversity at our institutions. That doesn't mean we stop doing the work.

Example: In the same biology class you will find two students: one took AP chemistry and the other came from a school that didn't have a chemistry teacher. Both deserved to be there but the latter would have been excluded without DEI initiatives (and inclusive teaching practices)

The UNC System has been doing DEI for as long as I can remember. North Carolina is a diverse state with multiple metropolitan counties (Wake, Mecklenburg, etc.) and many more rural counties (Edgecombe, Wataguga, etc.). Enrollment at UNC reflects that diversity.

In the ALINA trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib & 63.7% with standard chemotherapy. Full results & Research Summary: nej.md/3VUzf3M

Positive OS readout of STARGLO: glofit-GemOx vs R-GemOx in transplant ineligible R/R DLBCL Will be exciting to see the full results @mike_dickinson1